Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 36 recommendations for 18 medicines and 13 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
10. Medicines affecting the blood
  1. Acenocoumarol General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to warfarin for Other specified diseases of arteries or arterioles Therapeutic equivalent to warfarin for Venous thromboembolism Therapeutic equivalent to warfarin for Cerebral ischaemic stroke due to embolic occlusion Therapeutic equivalent to warfarin for Atrial fibrillation
  2. Apixaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  3. Cyanocobalamin General information
    Section
    Antianaemia medicines
    • .
    Indications
    Anaemias or other erythrocyte disorders
  4. Dabigatran General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
    Indications
    Venous thromboembolism Other specified atrial fibrillation
  5. Dalteparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  6. Darbepoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  7. Deferasirox General information
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias Therapeutic equivalent to deferoxamine for Thalassaemias
  8. Deferiprone General information
    Section
    Other medicines for haemoglobinopathies
    Indications
    Therapeutic equivalent to deferasirox for Other specified sickle cell disorders or other haemoglobinopathies Therapeutic equivalent to deferasirox for Thalassaemias
  9. Deferoxamine General information
    Section
    Other medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias
  10. Desmopressin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 150 µg per actuation (acetate)
    Indications
    Haemophilia A Von Willebrand disease
  11. Edoxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  12. Emicizumab General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial
    Indications
    Haemophilia A
  13. Enoxaparin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
    Indications
    Acute ischaemic heart disease Venous thromboembolism
  14. Epoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  15. Epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  16. Epoetin theta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  17. Erythropoiesis-stimulating agents General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
  18. Ferrous salt General information
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron
    • Oral > Solid > tablet: 60 to 65 mg elemental iron
    Indications
    Iron deficiency anaemia
  19. Ferrous salt + folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 60 mg iron + 2.8 mg
    • Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
    Indications
    Iron deficiency anaemia Clefts of lip, alveolus or palate Iron deficiency anaemia Anencephaly or similar anomalies Spina bifida
  20. Folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 400 µg
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    Indications
    Anencephaly or similar anomalies Spina bifida Cephalocele Folate deficiency anaemia
  21. Heparin sodium General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial
    Indications
    Acute ischaemic heart disease Unstable angina Venous thromboembolism
  22. Hydroxocobalamin General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
    Indications
    Megaloblastic anaemia due to vitamin B12 deficiency
  23. Hydroxycarbamide (hydroxyurea) General information
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies
  24. Methoxy polyethylene glycol-epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  25. Nadroparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  26. Phytomenadione General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1 mg per 0.5 mL in ampoule; 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution
    • Oral > Solid > tablet: 5 mg tablet
    Indications
    Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors Haemorrhagic or haematological disorders of fetus or newborn
  27. Protamine sulfate General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial
    Indications
    Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors
  28. Rivaroxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  29. Tranexamic acid General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Haemorrhage, not elsewhere classified
  30. Warfarin General information
    Section
    Medicines affecting coagulation
    • Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
    • Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
    Indications
    Other specified diseases of arteries or arterioles Venous thromboembolism Cerebral ischaemic stroke due to embolic occlusion Atrial fibrillation